Get The Best Care for Your Chronic Lymphocytic Leukemia (CLL)
The CLL Society Inc. is a patient–centric, physician–curated nonprofit organization focused on
patient education, support, and research. Dedicated to addressing the unmet needs of the Chronic Lymphocytic Leukemia (CLL) community,
our goal is to provide real, recent and relevant information and to be the “go to place” for CLL patients and caregivers.
What’s New in CLL?
- The trial that compared FCR to ibrutinib and rituximab for treatment naïve, non 17p deleted patients was the biggest news at ASH 2018. Here is a fresh perspective from Dr. Kay, one of the researchers. Watch the interview.
- At ASH 2018, Dr. Roeker discusses the early data from the CORE study that gives us a glimpse at why it is important to have a CLL specialist on your team. Watch the interview.
- We need to know the total cost of therapies, but it is remarkably hard information to get. Dr. Nabhan researched the cost of venetoclax versus chemotherapy or chemo-immunotherapy. Watch the interview.
- Dr. Nabhan left direct patient care and interventional research to see what other questions he could answer and what other ways he might help. In some ways, I have done the same, so this ASH interview was personal – Dr. Koffman.
CLL Society Expert Access™
Access to a CLL expert is critical to ensure receiving the best possible care and has proven to improve survival. In partnership with Verastem Oncology and InfiniteMD, the CLL Society is proud to offer this free second opinion program for CLL patients.
We Are in this Together
-
Pingback: ABT-199 (venetoclax) in Combination Treatment for CLL